Jessica Kendrick1, Pratik Shah2, Emily Andrews2, Zhiying You2, Kristen Nowak2, Andreas Pasch3, Michel Chonchol2. 1. Division of Renal Diseases and Hypertension, University of Colorado Denver, Aurora, Colorado; and Jessica.Kendrick@ucdenver.edu. 2. Division of Renal Diseases and Hypertension, University of Colorado Denver, Aurora, Colorado; and. 3. Department of Biomedical Research, University of Bern and Calciscon, Bern, Switzerland.
Abstract
BACKGROUND AND OBJECTIVES: We examined the effect of alkali replacement for metabolic acidosis on vascular endothelial function in patients with CKD. METHODS: We performed a pilot, prospective, open-label 14-week crossover study examining the effect of oral sodium bicarbonate treatment on vascular function in 20 patients with an eGFR of 15-44 ml/min per 1.73 m2 with low serum bicarbonate levels (16-21 mEq/L). Each period was 6 weeks in duration with a 2-week washout period in between. Patients were treated to goal serum bicarbonate of ≥23 mEq/L. The primary end point was change in brachial artery flow-mediated dilation (FMD) between treatment and control conditions. Secondary end points included changes in markers of inflammation, bone turnover, mineral metabolism, and calcification. RESULTS:Eighteen patients completed the study and were included in the primary efficacy analysis. The mean (SD) age and eGFR were 59 (12) years and 26 (8) ml/min per 1.73 m2, respectively. Serum bicarbonate increased significantly with sodium bicarbonate treatment (+2.7±2.9 mEq/L, P≤0.001), whereas there was no change in bicarbonate levels in the control group. FMD significantly improved after sodium bicarbonate therapy (mean±SD, FMD baseline: 4.1%±4.1%; 6 weeks: 5.2%±2.9%; P=0.04) There was no significant change in FMD in the control group (mean±SD, FMD baseline: 4.6%±3.1%; 6 weeks: 4.1%±3.4%; P=0.20). Compared with control, sodium bicarbonate treatment resulted in a significant increase in FMD (mean, 1.8%; 95% confidence interval, 0.3 to 3.3; P=0.02). There was no significant change in bone markers or serum calcification propensity with treatment. Serum phosphorus and intact fibroblast growth factor 23 increased significantly during treatment. CONCLUSIONS: Treatment of metabolic acidosis with sodium bicarbonate significantly improved vascular endothelial function in patients with stages 3b and 4 CKD.
RCT Entities:
BACKGROUND AND OBJECTIVES: We examined the effect of alkali replacement for metabolic acidosis on vascular endothelial function in patients with CKD. METHODS: We performed a pilot, prospective, open-label 14-week crossover study examining the effect of oral sodium bicarbonate treatment on vascular function in 20 patients with an eGFR of 15-44 ml/min per 1.73 m2 with low serum bicarbonate levels (16-21 mEq/L). Each period was 6 weeks in duration with a 2-week washout period in between. Patients were treated to goal serum bicarbonate of ≥23 mEq/L. The primary end point was change in brachial artery flow-mediated dilation (FMD) between treatment and control conditions. Secondary end points included changes in markers of inflammation, bone turnover, mineral metabolism, and calcification. RESULTS: Eighteen patients completed the study and were included in the primary efficacy analysis. The mean (SD) age and eGFR were 59 (12) years and 26 (8) ml/min per 1.73 m2, respectively. Serum bicarbonate increased significantly with sodium bicarbonate treatment (+2.7±2.9 mEq/L, P≤0.001), whereas there was no change in bicarbonate levels in the control group. FMD significantly improved after sodium bicarbonate therapy (mean±SD, FMD baseline: 4.1%±4.1%; 6 weeks: 5.2%±2.9%; P=0.04) There was no significant change in FMD in the control group (mean±SD, FMD baseline: 4.6%±3.1%; 6 weeks: 4.1%±3.4%; P=0.20). Compared with control, sodium bicarbonate treatment resulted in a significant increase in FMD (mean, 1.8%; 95% confidence interval, 0.3 to 3.3; P=0.02). There was no significant change in bone markers or serum calcification propensity with treatment. Serum phosphorus and intact fibroblast growth factor 23 increased significantly during treatment. CONCLUSIONS: Treatment of metabolic acidosis with sodium bicarbonate significantly improved vascular endothelial function in patients with stages 3b and 4 CKD.
Authors: Andreas Pasch; Stefan Farese; Steffen Gräber; Johanna Wald; Walter Richtering; Jürgen Floege; Willi Jahnen-Dechent Journal: J Am Soc Nephrol Date: 2012-09-06 Impact factor: 10.121
Authors: D S Celermajer; K E Sorensen; V M Gooch; D J Spiegelhalter; O I Miller; I D Sullivan; J K Lloyd; J E Deanfield Journal: Lancet Date: 1992-11-07 Impact factor: 79.321
Authors: Wei Chen; Michal L Melamed; Thomas H Hostetter; Carolyn Bauer; Amanda C Raff; Anthony L Almudevar; Amy Lalonde; Susan Messing; Matthew K Abramowitz Journal: BMC Nephrol Date: 2016-08-05 Impact factor: 2.388
Authors: Kalani L Raphael; Tamara Isakova; Joachim H Ix; Dominic S Raj; Myles Wolf; Linda F Fried; Jennifer J Gassman; Cynthia Kendrick; Brett Larive; Michael F Flessner; Susan R Mendley; Thomas H Hostetter; Geoffrey A Block; Ping Li; John P Middleton; Stuart M Sprague; Donald E Wesson; Alfred K Cheung Journal: J Am Soc Nephrol Date: 2019-12-17 Impact factor: 10.121
Authors: Miles D Witham; Margaret Band; Huey Chong; Peter T Donnan; Geeta Hampson; May Khei Hu; Roberta Littleford; Edmund Lamb; Philip A Kalra; Gwen Kennedy; Paul McNamee; Deirdre Plews; Petra Rauchhaus; Roy L Soiza; Deepa Sumukadas; Graham Warwick; Alison Avenell Journal: Health Technol Assess Date: 2020-06 Impact factor: 4.014
Authors: Wei Chen; Jessica Fitzpatrick; Jose M Monroy-Trujillo; Stephen M Sozio; Bernard G Jaar; Michelle M Estrella; Jishyra Serrano; Viktoriya Anokhina; Benjamin L Miller; Michal L Melamed; David A Bushinsky; Rulan S Parekh Journal: Am J Kidney Dis Date: 2020-08-13 Impact factor: 8.860